마이크로캐리어 시장 규모, 점유율, 동향 및 예측 : 제품 유형별, 소재별, 용도별, 최종사용자별, 지역별(2026-2034년)

The global microcarrier market size was valued at USD 1.8 Billion in 2025. Looking forward, IMARC Group estimates the market to reach USD 2.8 Billion by 2034, exhibiting a CAGR of 4.74% during 2026-2034. North America currently dominates the market, holding a significant market share of 42.2% in 2025. The region's robust healthcare system, continuous improvements in biopharmaceutical production, significant research expenditures, and strong demand for cell-based therapies and biologics all contribute to the microcarrier market share and drive this supremacy.

The growth of the market is primarily driven by the increasing demand for cell culture-based manufacturing processes in the biopharmaceutical industry. The rising prevalence of chronic diseases and the expanding need for biologics production further propel the market, as microcarriers are crucial for large-scale cell culture applications. For instance, SoloHill(R) Microcarriers from Sartorius Stedim Biotech GmbH are designed for expanding adherent cells in suspension culture. Available in both non-sterile autoclavable and sterile gamma-irradiated formats, these microcarriers facilitate easy cell attachment and growth without lengthy pre-conditioning steps. They feature solid modified polystyrene cores with proprietary surface modifications, enhancing cell detachment and performance across various cell types. Additionally, the shift towards personalized medicine and gene therapies, which require efficient cell production methods, is creating new opportunities. The development of advanced microcarrier technologies, offering enhanced performance and scalability, is also a significant factor. Moreover, the rising investment in research and development, coupled with improved regulatory frameworks, is fostering market expansion.

The United States microcarrier market growth benefits from a highly advanced healthcare system, robust pharmaceutical and biotechnology industries, and a strong emphasis on innovation. The rising demand for biologics, driven by both therapeutic and vaccine production, plays a pivotal role in market growth. Additionally, the country's extensive research infrastructure supports cell culture advancements and accelerates the development of new biopharmaceuticals. Increased adoption of gene therapies and personalized medicine also drives the demand for efficient manufacturing techniques, such as those offered by microcarriers. Moreover, the presence of leading companies and favorable government policies further supports the growth of the United States microcarrier market.

MICROCARRIER MARKET TRENDS:

Growing demand for biopharmaceuticals

Biopharmaceuticals have gained prominence due to their effectiveness in treating various diseases, and they play a pivotal role in the production of these biotherapeutics. According to a recent report, the global biopharmaceuticals market, valued at approximately USD 474.28 Billion in 2025, is projected to reach USD 1,369 Billion by 2034, highlighting the robust growth trajectory and market demand for biotherapeutic production platforms. As the pharmaceutical industry continues to shift towards biologics and personalized medicine, the demand for micro-carriers as a substrate for cell culture in bioprocessing is expected to increase. This factor is driven by the need for scalable and efficient cell expansion and cultivation processes, which carriers facilitate. The ongoing research and development efforts in the biopharmaceutical sector, coupled with the expansion of biomanufacturing facilities, are contributing to the sustained growth of the market. Moreover, the COVID-19 pandemic has further accelerated the demand for vaccines and therapeutic proteins, emphasizing the crucial role in bioproduction.

Advancements in cell-based therapies

The rapid advancements in cell-based therapies, particularly in regenerative medicine and immunotherapy, are fueling the growth of the market. As reported, the cell and gene therapy (CGT) sector received investments totaling USD 15.2 Billion in 2024, marking a 30% increase from the previous year. With over 3,000 developers and 2,000 clinical trials currently active, the infrastructure for cell-based therapies is rapidly expanding, further boosting the demand for microcarriers. These therapies involve the culturing and expansion of patient-derived cells or immune cells, which necessitates the use of as a support matrix for cell growth. The increasing focus on personalized medicine and the development of innovative treatments for conditions such as cancer, autoimmune diseases, and tissue regeneration have led to a rise in the demand. Additionally, the flexibility, scalability, and reproducibility offered by cell culture systems make them indispensable in the manufacturing of cell therapies, thus creating a positive microcarrier market outlook.

Expansion of stem cell research

Stem cell research continues to be a dynamic and promising field with applications in both basic research and clinical applications. They are widely utilized for the expansion of stem cells, whether for studying developmental processes or for therapeutic purposes. The stem cell manufacturing industry is projected to grow from USD 14.22 Billion in 2024 to USD 41.67 billion by 2034, driven by a CAGR of 11.35%, according to recent market data. In addition to this, the increasing investment in stem cell research, coupled with the rising interest in regenerative medicine, is propelling the market across the globe. Researchers and biotechnology companies rely on microcarriers to provide a controlled environment for the growth and differentiation of stem cells, which is essential for the development of cell-based therapies and tissue engineering. The microcarrier market forecast suggests continued growth, driven by advancements in stem cell and regenerative medicine research.

MICROCARRIER INDUSTRY SEGMENTATION:

Analysis by Product:

• Equipment
  • Bioreactors
  • Culture Vessels
  • Filtration Systems
  • Cell Counters
  • Accessories
• Consumables
  • Media
  • Reagents
  • Microcarrier Beads

Consumables stand as the largest component in 2025, holding around 72.2% of the market. Consumables comprises various consumable items used in cell culture, such as micro-carriers themselves, culture media, reagents, and disposables. They are the primary component of this segment, serving as the substrate for cell attachment and growth. The consumables segment is driven by the constant need for high-quality, sterile, and scalable materials for bioprocessing applications.

Analysis by Material Type:

• Alginate-based
• Collagen-based
• Dextran-based
• Polystyrene-based
• Others

Alginate-based leads the market in 2025. The alginate-based segment holds a dominant position in the market due to its versatility and widespread use. Alginate is a biocompatible polymer derived from seaweed, making it an attractive choice for cell culture applications. These carriers provide a suitable environment for the growth of various cell types and are particularly popular in the biopharmaceutical and regenerative medicine industries. Alginate-based variants offer excellent cell attachment properties and can be easily customized to support different cell cultures, contributing to their leading market share.

Analysis by Application:

• Vaccine Manufacturing
• Cell Therapy
• Others

Vaccine manufacturing leads the market in 2025. Vaccine manufacturing is the dominant segment in the market, driven by the critical role of in the production of vaccines. They serve as a platform for the cultivation of virus-infected cells or cells expressing vaccine antigens. They provide a controlled environment for the growth of these cells, allowing for efficient virus replication or antigen expression. With the increasing global demand for vaccines, especially in response to pandemics and emerging infectious diseases, the vaccine manufacturing segment is witnessing substantial growth. These carriers enable scalable and high-yield vaccine production, ensuring a steady supply to meet healthcare needs worldwide.

Analysis by End User:

• Pharmaceutical and Biotechnology Companies
• Academic and Research Institutes
• Contract Research Organizations (CROs)
• Others

Pharmaceutical and biotechnology companies leads the market with around 44.8% of market share in 2025. Pharmaceutical companies are the largest end-user segment in the market, primarily due to their extensive involvement in biopharmaceutical production. These companies rely on micro-carriers for the scalable and efficient cultivation of cells used in the manufacturing of biologics, including monoclonal antibodies, vaccines, and therapeutic proteins. They provide a controlled environment for cell growth, ensuring high yields and consistent product quality. As the demand for biopharmaceuticals continues to grow worldwide, pharmaceutical companies are continually expanding their biomanufacturing capacity, driving the demand.

Regional Analysis:

• North America
  • United States
  • Canada
• Asia Pacific
  • China
  • Japan
  • India
  • South Korea
  • Australia
  • Indonesia
  • Others
• Europe
  • Germany
  • France
  • United Kingdom
  • Italy
  • Spain
  • Russia
  • Others
• Latin America
  • Brazil
  • Mexico
  • Others
• Middle East and Africa

In 2025, North America accounted for the largest market share of 42.2%. North America stands as the largest segment in the market, driven by the presence of a well-established biopharmaceutical industry and advanced biomanufacturing facilities. For instance, as per industry reports, the biopharmaceutical market in North America captured the largest revenue share in 2024, with 52.60%. The United States hosts numerous pharmaceutical and biotechnology companies that heavily rely on these carriers for large-scale cell culture processes. The region's commitment to research and development, along with a robust healthcare infrastructure, further fuels the demand for biopharmaceuticals and microcarrier. Regulatory support and technological advancements in the bioprocessing sector also contribute to North America's leadership in the market.

KEY REGIONAL TAKEAWAYS:

UNITED STATES MICROCARRIER MARKET ANALYSIS

In 2025, the United States held a market share of around 90.60% in North America. The United States microcarrier market is witnessing significant growth, supported by strong investments in cell therapy research and biopharmaceutical innovations. The region's advanced healthcare infrastructure and favorable regulatory support for regenerative medicine are accelerating the adoption of microcarriers in commercial-scale manufacturing. Increasing government and private sector funding for stem cell and vaccine development is further contributing to market expansion. According to the American Society of Gene & Cell Therapy (ASGCT), of the 27 gene therapy trials initiated, 74% were for non-oncology indications in Q1 2025, 16% higher than the previous quarter, while 57% of the 79 trials initiated in Q1 focused on oncology, marking the highest oncology trial proportion over the past year in the U.S. This surge in diversified clinical activity is intensifying demand for robust and scalable microcarrier systems. Additionally, the shift toward continuous bioprocessing techniques is driving the demand for microcarriers in scalable and automated systems. The growing demand for personalized medicine and autologous cell therapies is boosting the use of microcarriers in research and production. Bioprocessing facilities, skilled professionals, and academic-industry partnerships are boosting market growth, enabling precise control and monitoring through digital tools and intellectual property protections for next-generation biologics and cell-based therapies.

EUROPE MICROCARRIER MARKET ANALYSIS

The microcarrier market in Europe is expanding steadily due to increased research activities in advanced tissue engineering and regenerative applications. A strong academic and clinical research environment is fostering the adoption of microcarriers in cell expansion and drug screening protocols. The push for sustainability in bioprocessing is encouraging the adoption of microcarrier systems that minimize resource usage and maximize yield. Moreover, regional efforts to scale up manufacturing capabilities are gaining traction. According to the Association of the British Pharmaceutical Industry (ABPI), enhancing the UK's ability to manufacture advanced cell therapies by leveraging initiatives such as the USD 660 Million multi-year Life Sciences Capital Grants Facility represents a significant opportunity for growth and investment in cutting-edge bioprocessing infrastructure. The market for cell-based models in toxicology testing is expanding due to regulatory initiatives, scalable culture systems, collaborations between research and biotechnology firms, public awareness, and harmonized biomanufacturing practices, which promote consistent quality in therapeutic development.

ASIA PACIFIC MICROCARRIER MARKET ANALYSIS

Asia Pacific's microcarrier market is experiencing rapid expansion driven by rising demand for affordable biologics and increased public investment in life sciences infrastructure. The region's growing emphasis on biotechnology-based innovation is fueling the development of microcarrier-compatible bioreactor systems. With the expansion of contract manufacturing organizations and academic-industry partnerships, the need for efficient and scalable cell culture platforms is accelerating. According to reports, the Indian biologics and biosimilars market is projected to reach USD 12 Billion by 2025, highlighting the region's expanding role in global biomanufacturing. Advances in 3D cell culture research and the growing focus on regenerative healthcare solutions are further contributing to adoption. Additionally, training initiatives aimed at improving technical expertise in bioprocessing are helping bridge skill gaps and promote technology uptake. The trend of decentralized healthcare manufacturing is also influencing the demand for compact and cost-effective microcarrier systems suitable for localized production settings.

LATIN AMERICA MICROCARRIER MARKET ANALYSIS

The Latin America microcarrier market is growing, supported by rising public and private sector interest in enhancing local biomanufacturing capabilities. The increasing focus on regional production of vaccines and biologics is promoting the adoption of microcarriers in scalable cell culture systems. According to RETS, the Ministry of Health has announced that starting in 2026, 60 Million vaccine doses for dengue will be produced annually, underscoring the need for robust cell culture technologies such as microcarriers to support large-scale production. Research institutions are progressively integrating microcarrier technology into advanced studies on cell expansion and therapeutic development. National healthcare resilience is fostering cell-based treatment platforms using microcarrier systems, while emerging urban biotechnology hubs promote local innovation and cross-sector collaboration in cell culture technologies.

MIDDLE EAST AND AFRICA MICROCARRIER MARKET ANALYSIS

The Middle East and Africa microcarrier market is witnessing gradual growth driven by the region's investment in healthcare modernization and scientific research infrastructure. There is a growing emphasis on fostering local biotechnological expertise and cell-based research capabilities. According to a report, Saudi Arabia's healthcare sector is undergoing unprecedented privatization under Vision 2030, transitioning over 290 hospitals and 2,300 institutions, with private sector involvement projected to rise from 25% to 35% by 2030. This structural shift is expected to accelerate the adoption of advanced bioprocessing technologies, including microcarrier systems, across both public and private facilities. Microcarriers are being integrated into cell therapy and biomedical projects, with collaborations between universities and research centers and government initiatives supporting domestic biologics production platforms.

COMPETITIVE LANDSCAPE:

The competitive landscape of the microcarrier market is marked by the presence of numerous key players, ranging from established multinational corporations to emerging biotechnology firms. Businesses are placing greater emphasis on innovating products, advancing technologies, and forming strategic collaborations to enhance their competitive standing in the market. For instance, in April 2025, TCS Biosciences Ltd. announced that they have become an official distributor of Smart MCs products, offering researchers in the UK and Europe access to advanced microcarriers, hydrogels, and microfluidics tools. These products support research by optimizing cell attachment and growth, enabling precise 3D cell culture, and enhancing fluid control for complex systems. Collaborations with academic and research institutions also play a significant role in advancing microcarrier technology. Manufacturers are introducing advanced microcarriers with enhanced performance characteristics, such as improved scalability and compatibility with various cell types, to meet the growing demands of cell-based therapies and biopharmaceutical production. Moreover, the market is witnessing increased investments in research and development, with a strong emphasis on expanding the application of microcarriers in stem cell therapy, vaccine production, and personalized medicine.

The report provides a comprehensive analysis of the competitive landscape in the microcarrier market with detailed profiles of all major companies, including:

• CESCO Bioengineering Co. Ltd.
• ChemoMetec A/S
• Corning Incorporated
• Cytiva (Danaher Corporation)
• Eppendorf AG
• Esco VacciXcell
• HiMedia Laboratories
• Lonza Group AG
• Merck KGaA
• Sartorius AG
• Thermo Fisher Scientific Inc.
• VWR International LLC (Avantor Inc.)

KEY QUESTIONS ANSWERED IN THIS REPORT

1. How big is the microcarrier market?

2. What is the future outlook of the microcarrier market?

3. What are the key factors driving the microcarrier market?

4. Which region accounts for the largest microcarrier market share?

5. Which are the leading companies in the global microcarrier market?

Table of Contents

1 Preface

2 Scope and Methodology

• 2.1 Objectives of the Study
• 2.2 Stakeholders
• 2.3 Data Sources
  • 2.3.1 Primary Sources
  • 2.3.2 Secondary Sources
• 2.4 Market Estimation
  • 2.4.1 Bottom-Up Approach
  • 2.4.2 Top-Down Approach
• 2.5 Forecasting Methodology

3 Executive Summary

4 Introduction

• 4.1 Overview
• 4.2 Key Industry Trends

5 Global Microcarrier Market

• 5.1 Market Overview
• 5.2 Market Performance
• 5.3 Impact of COVID-19
• 5.4 Market Forecast

6 Market Breakup by Product

• 6.1 Equipment
  • 6.1.1 Market Trends
  • 6.1.2 Key Segments
    • 6.1.2.1 Bioreactors
    • 6.1.2.2 Culture Vessels
    • 6.1.2.3 Filtration Systems
    • 6.1.2.4 Cell Counters
    • 6.1.2.5 Accessories
  • 6.1.3 Market Forecast
• 6.2 Consumables
  • 6.2.1 Market Trends
  • 6.2.2 Key Segments
    • 6.2.2.1 Media
    • 6.2.2.2 Reagents
    • 6.2.2.3 Microcarrier Beads
  • 6.2.3 Market Forecast

7 Market Breakup by Material Type

• 7.1 Alginate-based
  • 7.1.1 Market Trends
  • 7.1.2 Market Forecast
• 7.2 Collagen-based
  • 7.2.1 Market Trends
  • 7.2.2 Market Forecast
• 7.3 Dextran-based
  • 7.3.1 Market Trends
  • 7.3.2 Market Forecast
• 7.4 Polystyrene-based
  • 7.4.1 Market Trends
  • 7.4.2 Market Forecast
• 7.5 Others
  • 7.5.1 Market Trends
  • 7.5.2 Market Forecast

8 Market Breakup by Application

• 8.1 Vaccine Manufacturing
  • 8.1.1 Market Trends
  • 8.1.2 Market Forecast
• 8.2 Cell Therapy
  • 8.2.1 Market Trends
  • 8.2.2 Market Forecast
• 8.3 Others
  • 8.3.1 Market Trends
  • 8.3.2 Market Forecast

9 Market Breakup by End User

• 9.1 Pharmaceutical and Biotechnology Companies
  • 9.1.1 Market Trends
  • 9.1.2 Market Forecast
• 9.2 Academic and Research Institutes
  • 9.2.1 Market Trends
  • 9.2.2 Market Forecast
• 9.3 Contract Research Organizations (CROs)
  • 9.3.1 Market Trends
  • 9.3.2 Market Forecast
• 9.4 Others
  • 9.4.1 Market Trends
  • 9.4.2 Market Forecast

10 Market Breakup by Region

• 10.1 North America
  • 10.1.1 United States
    • 10.1.1.1 Market Trends
    • 10.1.1.2 Market Forecast
  • 10.1.2 Canada
    • 10.1.2.1 Market Trends
    • 10.1.2.2 Market Forecast
• 10.2 Asia-Pacific
  • 10.2.1 China
    • 10.2.1.1 Market Trends
    • 10.2.1.2 Market Forecast
  • 10.2.2 Japan
    • 10.2.2.1 Market Trends
    • 10.2.2.2 Market Forecast
  • 10.2.3 India
    • 10.2.3.1 Market Trends
    • 10.2.3.2 Market Forecast
  • 10.2.4 South Korea
    • 10.2.4.1 Market Trends
    • 10.2.4.2 Market Forecast
  • 10.2.5 Australia
    • 10.2.5.1 Market Trends
    • 10.2.5.2 Market Forecast
  • 10.2.6 Indonesia
    • 10.2.6.1 Market Trends
    • 10.2.6.2 Market Forecast
  • 10.2.7 Others
    • 10.2.7.1 Market Trends
    • 10.2.7.2 Market Forecast
• 10.3 Europe
  • 10.3.1 Germany
    • 10.3.1.1 Market Trends
    • 10.3.1.2 Market Forecast
  • 10.3.2 France
    • 10.3.2.1 Market Trends
    • 10.3.2.2 Market Forecast
  • 10.3.3 United Kingdom
    • 10.3.3.1 Market Trends
    • 10.3.3.2 Market Forecast
  • 10.3.4 Italy
    • 10.3.4.1 Market Trends
    • 10.3.4.2 Market Forecast
  • 10.3.5 Spain
    • 10.3.5.1 Market Trends
    • 10.3.5.2 Market Forecast
  • 10.3.6 Russia
    • 10.3.6.1 Market Trends
    • 10.3.6.2 Market Forecast
  • 10.3.7 Others
    • 10.3.7.1 Market Trends
    • 10.3.7.2 Market Forecast
• 10.4 Latin America
  • 10.4.1 Brazil
    • 10.4.1.1 Market Trends
    • 10.4.1.2 Market Forecast
  • 10.4.2 Mexico
    • 10.4.2.1 Market Trends
    • 10.4.2.2 Market Forecast
  • 10.4.3 Others
    • 10.4.3.1 Market Trends
    • 10.4.3.2 Market Forecast
• 10.5 Middle East and Africa
  • 10.5.1 Market Trends
  • 10.5.2 Market Breakup by Country
  • 10.5.3 Market Forecast

11 SWOT Analysis

• 11.1 Overview
• 11.2 Strengths
• 11.3 Weaknesses
• 11.4 Opportunities
• 11.5 Threats

12 Value Chain Analysis

13 Porters Five Forces Analysis

• 13.1 Overview
• 13.2 Bargaining Power of Buyers
• 13.3 Bargaining Power of Suppliers
• 13.4 Degree of Competition
• 13.5 Threat of New Entrants
• 13.6 Threat of Substitutes

14 Price Analysis

15 Competitive Landscape

• 15.1 Market Structure
• 15.2 Key Players
• 15.3 Profiles of Key Players
  • 15.3.1 CESCO Bioengineering Co. Ltd.
    • 15.3.1.1 Company Overview
    • 15.3.1.2 Product Portfolio
  • 15.3.2 ChemoMetec A/S
    • 15.3.2.1 Company Overview
    • 15.3.2.2 Product Portfolio
    • 15.3.2.3 Financials
  • 15.3.3 Corning Incorporated
    • 15.3.3.1 Company Overview
    • 15.3.3.2 Product Portfolio
    • 15.3.3.3 Financials
    • 15.3.3.4 SWOT Analysis
  • 15.3.4 Cytiva (Danaher Corporation)
    • 15.3.4.1 Company Overview
    • 15.3.4.2 Product Portfolio
  • 15.3.5 Eppendorf AG
    • 15.3.5.1 Company Overview
    • 15.3.5.2 Product Portfolio
    • 15.3.5.3 SWOT Analysis
  • 15.3.6 Esco VacciXcell
    • 15.3.6.1 Company Overview
    • 15.3.6.2 Product Portfolio
  • 15.3.7 HiMedia Laboratories
    • 15.3.7.1 Company Overview
    • 15.3.7.2 Product Portfolio
  • 15.3.8 Lonza Group AG
    • 15.3.8.1 Company Overview
    • 15.3.8.2 Product Portfolio
    • 15.3.8.3 Financials
    • 15.3.8.4 SWOT Analysis
  • 15.3.9 Merck KGaA
    • 15.3.9.1 Company Overview
    • 15.3.9.2 Product Portfolio
    • 15.3.9.3 Financials
    • 15.3.9.4 SWOT Analysis
  • 15.3.10 Sartorius AG
    • 15.3.10.1 Company Overview
    • 15.3.10.2 Product Portfolio
    • 15.3.10.3 Financials
    • 15.3.10.4 SWOT Analysis
  • 15.3.11 Thermo Fisher Scientific Inc.
    • 15.3.11.1 Company Overview
    • 15.3.11.2 Product Portfolio
    • 15.3.11.3 Financials
    • 15.3.11.4 SWOT Analysis
  • 15.3.12 VWR International LLC (Avantor Inc.)
    • 15.3.12.1 Company Overview
    • 15.3.12.2 Product Portfolio